Key clinical point:
Major finding: The overall response rate was 53%.
Study details: A phase 1 trial involving 30 patients.
Disclosures: Dr. Advani reported receiving research funding from Takeda/Millenium, and serving as a consultant for Pfizer.
Source: Advani A et al. ASH 2017, Abstract 150.
Advani A et al. ASH 2017, Abstract 150.
This Week's Must Reads
Relevance of Health Literacy to CV Health, Circulation; ePub 2018 Jun 4; Magnani, et al
Diabetes & Long-Term Kidney Disease, Diabetes Care; ePub 2018 Jun 1; Warren, et al
Maternal Loss of Control Over Eating, Am J Clin Nutr; ePub 2018 Jun 5; Micali, et al
Efficacy of Brief Behavioral Treatment for Insomnia, Sleep Medicine; ePub 2018 Jun 2; McCrae, et al
Opioid-Related Adverse Events in Surgical Patients, JAMA Surg; ePub 2018 May 23; Shafi, et al
Must Reads in Oncology
ACS Recommends CRC Screening at Age 45, CA Cancer J Clin; ePub 2018 May 30; Wolf, et al
Lung Cancer Incidence in Young Men & Women, N Engl J Med; 2018 May 24; Jemal, et al
Risk Prediction Models for Lung Cancer Screening , Ann Intern Med; ePub 2018 May 15; Katki, et al
USPSTF: Screening for Prostate Cancer, JAMA; 2018 May 8; Grossman, et al
Cancer Incidence Rates in HIV-Infected Adults, Ann Intern Med; ePub 2018 May 8; Shiels, et al